|
|
|
|
Biogen Beats & Guides Higher
Biogen Idec Inc.(BIIB) reported fourth quarter earnings per share of $1.18, beating the Zacks Consensus Estimate of $1.05. The company reported earnings of 91 cents in the year-ago period. Performance was driven by higher revenues and lower expenses.
|
|
|
Biogen Beats & Guides Higher - Zibb.com
Companies: Biogen Idec Inc (BIIB), Elan Corp.Plc (ELN) Biogen Idec Inc. (BIIB) reported fourth quarter earnings per share of $1.18, beating the Zacks Consensus Estimate of $1.05. The company reported earnings of 91 cents in the year-ago period.
|
|
|
Biogen Beats & Guides Higher - Zibb.com
Companies: Biogen Idec Inc (BIIB), Elan Corp.Plc (ELN) Biogen Idec Inc. (BIIB) reported fourth quarter earnings per share of $1.18, beating the Zacks Consensus Estimate of $1.05. The company reported earnings of 91 cents in the year-ago period.
|
|
|
Biogen Beats & Guides Higher - Zibb.com
Companies: Biogen Idec Inc (BIIB), Elan Corp.Plc (ELN) Biogen Idec Inc. (BIIB) reported fourth quarter earnings per share of $1.18, beating the Zacks Consensus Estimate of $1.05. The company reported earnings of 91 cents in the year-ago period.
|
|
|
Biogen Beats & Guides Higher
Biogen Idec Inc.(BIIB - Performance was driven by higher revenues and lower expenses. Revenues increased 5% to $1.1 billion, with Tysabri and Avonex being the primary growth drivers. For the full year, the company reported earnings of $4.03, well...
|
|
|
Elan Q4 Pre-Tax Loss Narrows On Strong Tysabri Sales - Update
2/10/2010 6:07 AM ET RELATED NEWS Trade ELN now with TOP MARKET NEWS (RTTNews) - Elan Corporation, plc (ELN: News ), a neuroscience-based biotechnology company, Wednesday, reported a narrower loss before tax for the fourth quarter, as revenues grew 11% driven...
|
|
|
Number of Tysabri infusions increases PML risk: FDA
The risk of developing a potentially deadly brain infection from multiple sclerosis drug Tysabri (natalizumab) increased with the number of infusions received, US drug regulators have warned.The Food and Drug Administration (FDA) said its decision to...
|
|
|
Irish drugmaker Elan records Q4 loss, sees rebound
Elan Corp.PLC said Wednesday it slumped to a loss in the fourth quarter, but the Irish drugmaker forecast a 2010 rebound as sales for its key multiple sclerosis-fighting drug, Tysabri, continue to grow. Associated Press Writer DUBLIN Elan Corp. PLC...
|
|
|
Irish drugmaker Elan records 4th-quarter loss, sees 2010 rebound amid strong Tysabri sales
DUBLIN Elan Corp.PLC said Wednesday it slumped to a loss in the fourth quarter, but the Irish drugmaker forecast a 2010 rebound as sales for its key multiple sclerosis-fighting drug, Tysabri, continue to grow. The Dublin-based company said its net...
|
|
|
Irish drugmaker Elan records Q4 loss, sees rebound
DUBLIN -- Elan Corp.PLC said Wednesday it slumped to a loss in the fourth quarter, but the Irish drugmaker forecast a 2010 rebound as sales for its key multiple sclerosis-fighting drug, Tysabri, continue to grow. The Dublin-based company said its net...
|
|
|
Irish drugmaker Elan records Q4 loss, sees rebound
DUBLIN Elan Corp.PLC said Wednesday it slumped to a loss in the fourth quarter, but the Irish drugmaker forecast a 2010 rebound as sales for its key multiple sclerosis-fighting drug, Tysabri, continue to grow. The Dublin-based company said its net...
|
|
|
Irish drugmaker Elan records Q4 loss, sees rebound
DUBLIN -- Elan Corp.PLC said Wednesday it slumped to a loss in the fourth quarter, but the Irish drugmaker forecast a 2010 rebound as sales for its key multiple sclerosis-fighting drug, Tysabri, continue to grow. The Dublin-based company said its net...
|
|
|
Irish drugmaker Elan records Q4 loss, sees rebound (AP)
DUBLIN Elan Corp.PLC said Wednesday it slumped to a loss in the fourth quarter, but the Irish drugmaker forecast a 2010 rebound as sales for its key multiple sclerosis-fighting drug, Tysabri, continue to grow. The Dublin-based company said its net...
|
|
|
Irish drugmaker Elan records Q4 loss, sees rebound
DUBLIN (AP) - Elan Corp.PLC said Wednesday it slumped to a loss in the fourth quarter, but the Irish drugmaker forecast a 2010 rebound as sales for its key multiple sclerosis-fighting drug, Tysabri, continue to grow. The Dublin-based company said its...
|
|
|
Irish drugmaker Elan records Q4 loss, sees rebound
DUBLIN (AP) - Elan Corp.PLC said Wednesday it slumped to a loss in the fourth quarter, but the Irish drugmaker forecast a 2010 rebound as sales for its key multiple sclerosis-fighting drug, Tysabri, continue to grow. The Dublin-based company said its...
|
|
|
Irish Drugmaker Elan Records Q4 Loss, Sees Rebound
DUBLIN (AP) - Elan Corp.PLC said Wednesday it slumped to a loss in the fourth quarter, but the Irish drugmaker forecast a 2010 rebound as sales for its key multiple sclerosis-fighting drug, Tysabri, continue to grow.The Dublin-based company said its...
|
|
|
Irish Drugmaker Elan Records Q4 Loss, Sees Rebound
DUBLIN (AP) - Elan Corp.PLC said Wednesday it slumped to a loss in the fourth quarter, but the Irish drugmaker forecast a 2010 rebound as sales for its key multiple sclerosis-fighting drug, Tysabri, continue to grow.The Dublin-based company said its...
|
|
|
Irish Drugmaker Elan Records Q4 Loss, Sees Rebound
DUBLIN (AP) - Elan Corp.PLC said Wednesday it slumped to a loss in the fourth quarter, but the Irish drugmaker forecast a 2010 rebound as sales for its key multiple sclerosis-fighting drug, Tysabri, continue to grow.The Dublin-based company said its...
|
|
|
Irish Drugmaker Elan Records Q4 Loss, Sees Rebound
DUBLIN (AP) - Elan Corp.PLC said Wednesday it slumped to a loss in the fourth quarter, but the Irish drugmaker forecast a 2010 rebound as sales for its key multiple sclerosis-fighting drug, Tysabri, continue to grow.The Dublin-based company said its...
|
|
|
Irish drugmaker Elan records Q4 loss, sees rebound
Elan Corp.PLC said Wednesday it slumped to a loss in the fourth quarter, but the Irish drugmaker forecast a 2010 rebound as sales for its key multiple sclerosis-fighting drug, Tysabri, continue to grow. The Dublin-based company said its net loss in...
|
|
|
Irish drugmaker Elan records Q4 loss, sees rebound
DUBLIN Elan Corp.PLC said Wednesday it slumped to a loss in the fourth quarter, but the Irish drugmaker forecast a 2010 rebound as sales for its key multiple sclerosis-fighting drug, Tysabri, continue to grow. The Dublin-based company said its net...
|
|
|
Irish Drugmaker Elan Records Q4 Loss, Sees Rebound
DUBLIN (AP) -- said Wednesday it slumped to a loss in the fourth quarter, but the Irish drugmaker forecast a 2010 rebound as sales for its key multiple sclerosis-fighting drug, Tysabri, continue to grow.The Dublin-based company said its net loss in the...
|
|
|
Irish drugmaker Elan records Q4 loss, sees rebound
DUBLIN (AP) - Elan Corp.PLC said Wednesday it slumped to a loss in the fourth quarter, but the Irish drugmaker forecast a 2010 rebound as sales for its key multiple sclerosis-fighting drug, Tysabri, continue to grow. The Dublin-based company said its...
|
|
|
Irish drugmaker Elan records Q4 loss, sees rebound
DUBLIN (AP) - Elan Corp.PLC said Wednesday it slumped to a loss in the fourth quarter, but the Irish drugmaker forecast a 2010 rebound as sales for its key multiple sclerosis-fighting drug, Tysabri, continue to grow. The Dublin-based company said its...
|
|
|
Irish drugmaker Elan records Q4 loss, sees rebound
DUBLIN (AP) -- Elan Corp.PLC said Wednesday it slumped to a loss in the fourth quarter, but the Irish drugmaker forecast a 2010 rebound as sales for its key multiple sclerosis-fighting drug, Tysabri, continue to grow. The Dublin-based company said...
|
